Animal models for the negative symptoms of schizophrenia

Behavioural Pharmacology

Volumn 11, Issue 3-4, 2000, Pages 223-233

  Ellenbroek, B A ^a   Cools, A R ^a  

^a Dept of Psychoneuropharmacology ^*

Author keywords

Animal models; Negative symptoms; Positive symptoms; Schizophrenia

Indexed keywords

AMISULPRIDE; AMPHETAMINE; APOMORPHINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; METHYLAZOXYMETHANOL; NEUROLEPTIC AGENT; OLANZAPINE; PHENCYCLIDINE; PSYCHEDELIC AGENT; QUETIAPINE; RISPERIDONE; SULPIRIDE;

ANHEDONIA; ANIMAL MODEL; BEHAVIOR DISORDER; CHRONICITY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG INDUCED DISEASE; DRUG MECHANISM; EXPERIMENTAL MODEL; HUMAN; NEGATIVE SYNDROME; NONHUMAN; PSYCHOSOCIAL WITHDRAWAL; REVIEW; SCHIZOPHRENIA;

EID: 0033923220     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200006000-00006     Document Type: Review

References (108)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC: American Psychiatric Press.
2. Andreasen NC, Olsen SA (1982). Negative vs. positive schizophrenia. Definition and validation. Arch Gen Psychiatry 39:789-794.
3. Angrist B (1994). Amphetamine psychosis: clinical variants of the syndrome. In: Amphetamine and its Analogs. Psychopharmacology, Toxicology and Abuse. Cho AK, Segal DS (editors). San Diego: Academic Press, pp. 387-414.
4. Angrist B, Sathananthan G, Wilk S, Gershon S (1974). Amphetamine psychosis: behavioural and biochemical aspects. J Psychiatr Res 11:13-23.
5. Angrist B, Peselow E, Rubinstein M, Corwin J, Rotrosen J (1982). Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology 78:128-130.
6. Bakshi VP, Geyer MA (1995). Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 122:198-201.
7. Becker A, Grecksch G, Bernstein HG, Hollt V, Bogerts B (1999). Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis. Psychopharmacology 144:333-338.
8. Bellack AS, Morrison RL, Wixted JT, Mueser KT (1990). An analysis of social competence in schizophrenia. Br J Psychiatry 156:809-818.
9. Bodi T, Share I, Levy H, Moyer JH (1959). Clinical trials of phencyclidine (sernyl) in patients with psychoneurosis. Antibiot Med Clin Trials 6:79-84.
10. Borsini F, Bendotti C, Samnin R (1985). Salbutamol, d-amphetamine and d-fenfluramine reduce sucrose intake in freely fed rats by acting on different neurochemical mechanisms. Int J Obes Relat Metab Disord 9:277-283.
11. Bozarth MA (1991). The mesolimbic dopamine system as a model reward system. In: The Mesolimbic Dopamine System: From Motivation to Action. Willner P, Scheel KJ (editors). Chichester: John Wiley and Sons, pp. 301-330.
12. Brown F, Campbell W, Mitchell PJ, Randall K (1985). Dopamine autoreceptors and the effects of drugs on locomotion and dopamine synthesis. Br J Pharmacol 84:853-860.
13. Carlezon WA, Wise RA (1993). Phencyclidine-induced potentiation of brain stimulation reward: acute effects are not altered by repeated administration. Psychopharmacology 111:402-408.
14. Carman J, Peuskens J, vanGeneugden A (1995). Risperidone in the treatment of negative symptoms: a meta-analysis. Int Clin Psychopharmacol 10:207-213.
15. Carnoy P, Ravard S, Wemerman B, Soubrie Ph, Simon P (1986). Behavioural deficits induced by low doses of apomorphine in rats: evidence for a motivational and cognitive dysfunction which discriminates neuroleptic drugs. Pharmacol Biochem Behav 25:503-509.
16. Carpenter-WT J, Heinrichs DW, Wagman AM (1988). Deficit and non deficit forms of schizophrenia: the concept. Am J Psychiatry 145:578-583.
17. Connell P. (1958). Amphetamine Psychosis. London: Oxford University Press.
18. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW (1995). Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology 120:67-74.
19. Crow TJ (1980). Molecular pathology of schizophrenia: more than one dimension of pathology? BMJ 280:66-68.
20. Ellenbroek BA (1991). The ethological analysis of monkeys in a social setting as an animal model for schizophrenia. In: Animal Models in Psychopharmacology. Olivier B, Mos J, Slangen JL (editors). Basel: Birkhauser, pp. 265-284.
21. Ellenbroek BA, Cools AR (1990). Animal models with construct validity for schizophrenia. Behav Pharmacol 1:469-490.
22. Ellenbroek BA, Cools AR (1995a). Animal models of psychotic disturbances. In: Advances in the Neurobiology of Schizophrenia. den Boer JA, Westenberg HGM, van Praag HM (editors). Chichester: John Wiley and Sons, pp. 89-109.
23. Ellenbroek BA, Cools AR (1995b). Maternal separation reduces latent inhibition in the conditioned taste aversion paradigm. Neurosci Res Commun 17:27-33.
24. Ellenbroek BA, Cools AR (1998). The neurodevelopmental hypothesis of schizophrenia: clinical evidence and animal models. Neurosci Res Commun 22:127-136.
25. Ellenbroek BA, Willemen AP, Cools AR (1989). Are antagonists of dopamine D1 receptors drugs that attenuate both positive and negative symptoms of schizophrenia? A pilot study in Java monkeys. Neuropsychopharmacology 2:191-199.
26. Ellenbroek BA, Lubbers LJ, Cools AR (1996). Activity of 'seroquel' (ICI 204,636) in animal models for atypical properties of antipsychotics: a comparison with clozapine. Neuropsychopharmacology 15:406-416.
27. Ellenbroek BA, Knobbout DK, Cools AR (1997). The role of mesolimbic and nigrostriatal dopamine in latent inhibition as measured in the conditioned taste aversion paradigm. Psychopharmacology 129:112-120.
28. Ellenbroek BA, van-den-Kroonenberg PTJM, Cools AR (1998). The effects of an early stressful life event on sensorimotor gating in adult rats. Schizophr Res 30:251-260.
29. Ellenbroek BA, Sams Dodd F, Cools AR (2000). Simulation models for schizophrenia. In: Atypical Antipsychotics. Ellenbroek BA, Cools AR (editors). Basel: Birkhauser Verlag pp 121-142.
30. Ellison G (2000). Monoamine neurotoxins: selective and delayed effects on behavior in colonies of laboratory rats. Brain Res 101:81-92.
31. Emerich DF, Sanberg PR (1991). Neuroleptic dysphoria. Biol Psychiatry 29:201-203.
32. Erard R, Luisada PV, Peele R (1980). The PCP psychosis: prolonged intoxication or drug-precipitated functional illness? J Psychedelic Drugs 12:235-251.
33. Erlenmeyer KL, Cornblatt BA, Rock D, Roberts S, Bell M, West A (1993). The New York high-risk project: anhedonia, attentional deviance and psychopathology. Schizophr Bull 19:141-153.
34. Frith CD, Friston KJ, Herold S, Silbersweig D, Fletcher P, Cahill C, Dolan RJ, Frackowiak RS, Liddle PF (1995). Regional brain activity in chronic schizophrenic patients during the performance of a verbal fluency task. Br J Psychiatry 167:343-349.
35. Gambill JD, Kornetsky C (1976). Effects of chronic d-amphetamine on social behavior of the rat: implications for an animal model of paranoid schizophrenia. Psychopharmacology 50:215-223.
36. Geyer MA, Markou A (1995). Animal models of psychiatric disorders. In: Psychopharmacology: The Fourth Generation of Progress. Bloom FE, Kupfer DJ (editors). New York: Raven Press, pp. 787-798.
37. Geyer MA, Wilkinson LS, Humby T, Robbins TW (1993). Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biol Psychiatry 34:361-372.
38. Green MF, Nuechterlein KH, Ventura J, Mintz J (1990). The temporal relationship between depressive and psychotic symptoms in recent-onset schizophrenia. Am J Psychiatry 147:179-182.
39. Greifenstein FE, Yoshitake J, DeValut M, Gajewski JE (1958). A study of 1-aryl cyclohexyl amine for anesthesia. Anesth Analg 37:283-294.
40. Griffith JD, Cavanaugh J, Held J, Oates JA (1972). Dextramphetamine evaluation of psychotomimetic properties in man. Arch Gen Psychiatry 26:97-100.
41. Hafner H, Maurer K, Loffler W, Riecher RA (1993). The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 162:80-86.
42. Hall FS, Humby T, Wilkinson LS, Robbins TW (1997). The effects of isolation-rearing on sucrose consumption in rats. Physiol Behav 62:291-297.
43. Hall FS, Huang S, Fong GW, Pert A, Linnoila M (1998). Effects of isolation-rearing on voluntary consumption of ethanol, sucrose and saccharin solutions in Fawn hooded and Wistar rats. Psychopharmacology 139:216.
44. Hirsch SR, Jolley AG, Barnes TE, Liddle PF, Curson DA, Patel A, York A, Bercu S, Patel M (1989). Dysphoric and depressive symptoms in chronic schizophrenia. Schizophr Res 2:259-264.
45. Hirsch SR, Link CGG, Goldstein JM, Arvanitis LA (1996). ICI 204,636: a new atypical antipsychotic drug. Br J Psychiatry 168:45-56.
46. Hogan TP, Awad AG (1992). Subjective response to neuroleptics and outcome on schizophrenia: a re-examination comparing two measures. Psychol Med 22:347-352.
47. Itil T, Keskiner A, Kiremitci N, Holden JMC (1967). Effect of phencyclidine in chronic schizophrenics. Can Psychiat Assoc J 12:209-212.
48. Jann MW (1991). Clozapine. Pharmacotherapy 11:179-195.
49. Kalant OJ (1973). The Amphetamines: Toxicity and Addiction. Toronto: University Toronto Press.
50. Kane JM (1999). Pharmacologic treatment of schizophrenia. Biol Psychiatry 46:1396-1408.
51. Knights A, Hirsch SR (1981). 'Revealed' depression and drug treatment for schizophrenia. Arch Gen Psychiatry 38:806-811.
52. Knobbout DA, Ellenbroek BA, Cools AR (1996). The influence of social structure on social isolation in amphetamine-treated Java monkeys (Macaca fascicularis). Behav Pharmacol 7:417-429.
53. Kornetsky C, Esposito RU (1979). Euphorigenic drugs: effects on the reward pathways of the brain. Fed Proc 38:2473-2476.
54. Levine S (1994). The ontogeny of the hypothalamic-pituitary-adrenal axis. The influence of maternal factors. Ann NY Acad Sci 746:275-288.
55. Liddle PF (1987). The symptoms of chronic schizophrenia: a re-examination of the positive-negative dichotomy. Br J Psychiatry 151:145-151.
56. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Frackowiak RJ (1992a). Cerebral blood flow and mental processes in schizophrenia. J R Soc Med 85:224-227.
57. Liddle PF, Friston KJ, Frith CD, Jones T, Hirsch SR, Frackowiak RS (1992b). Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 160:179-189.
58. Lieberman JA, Kane JM, Alvir J (1987). Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 91:415-533.
59. Lipska BK, Jaskiw GE, Weinberger DR (1993). Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 9:67-75.
60. Lipska BK, Swerdlow NR, Geyer MA, Jaskiw GE, Braff DL, Weinberger DR (1995). Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology 122:35-43.
61. Ljungberg T (1987). Blockade by neuroleptics of water intake and operant responding for water in the rat: anhedonia, motor deficit or both? Pharmacol Biochem Behav 27:341-350.
62. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959). Study of a new schizophrenomimetic drug - sernyl. Am Med Assoc Arch Neurol Psychiatry 81:363-369.
63. Mansbach RS, Geyer MA (1989). Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2:299-308.
64. Mansbach RS, Geyer MA, Braff DL (1988). Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology 94:507-514.
65. Matsumoto H, Spatz M, Laquer GL (1972). Quantitative changes with age in the DNA content of methylazoxymethanol-induced microencephalic rat brain. J Neurochem 19:297-306.
66. Miczek KA, Yoshimura H (1982). Disruption of primate social behavior by d-amphetamine and cocaine: differential antagonism by antipsychotics. Psychopharmacology 76:163-171.
67. Mueser KT, Bellack AS, Morrison RL, Wixted JT (1990). Social competence in schizophrenia: premorbid adjustment, social skill, and domains of functioning. J Psychiatr Res 24:51-63.
68. Muscat R, Willner P (1989). Effects of selective dopamine receptor antagonists on sucrose consumption and preference. Psychopharmacology 99:98-102.
69. Myerson A (1922). Anhedonia. Am J Psychiatry 2:87-111.
70. Myerson BJ, Hoglund AU (1981). Exploratory and soci-sexual behaviour in the male laboratory rat: a methodological approach for the investigation of drug action. Acta Pharmacol Toxicol 48:168-180.
71. Olds J, Milner P (1954). Positive reinforcement produced by electrical stimulation of septal areas and other brain regions of rat brain. J Comp Physiol Psychol 47:419-427.
72. Orthen Gambill N (1985). Sucrose intake unaffected by fenfluramine but suppressed by amphetamine administration. Psychopharmacology 87:25-29.
73. Ossowska K, Pietraszek M, Wardas J, Nowak G, Wolfarth S (1999). Influence of long-lasting administration of neuroleptics on cortical NMDA receptors and phencyclidine-induced deficit in the sensorimotor gating in rats. Pol J Pharmacol 51:49-53.
74. Papp M, Willner P, Muscat R (1991). An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress. Psychopharmacology 104:255-259.
75. Pilowsky LS, Kerwin RW, Murray RM (1993). Schizophrenia: a neurodevelopmental perspective. Neuropsychopharmacology 9:83-91.
76. Poncelet M, Chermat R, Soubrie P, Simon P (1983). The progressive ratio schedule as a model for studying the psychomotor stimulant activity of drugs in the rat. Psychopharmacology 80:184-189.
77. Porsolt RD, Lenegre A, McArthur RA (1991). Pharmacological models of depression. In: Animal Models in Psychopharmacology. Olivier B, Mos J, Slangen JL (editors). Basel: Birkhauser, pp. 137-159.
78. Rado S (1962). Psychoanalysis of Behavior: Collected Papers, vol 2. New York: Grune and Stratton.
79. Sams Dodd F (1996). Phencyclidine-induced stereotyped behaviour and social isolation in the rat: a possible animal model of schizophrenia. Behav Pharmacol 7:3-23.
80. Sams Dodd F (1997). Effects of novel antipsychotic drugs on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav Pharmacol 8:196-215.
81. Sams Dodd F (1998a). A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine. Neuropsychopharmacology 18:293-304.
82. Sams Dodd F (1998b). Effects of continuous d-amphetamine or phencyclidine administration on social behaviour, stereotyped behaviour and locomotor activity in rats. Neuropsychopharmacology 19:18-25.
83. Sams Dodd F, Lipska BK, Weinberger DR (1997). Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology 132:303-310.
84. Schiorring E (1979). Changes in individual and social behavior induced by amphetamine and related compounds in monkeys and man. In: Cocaine and Other Stimulants. Ellinwood EH, Kilbey M (editors). New York: Plenum Press, pp. 481-522.
85. Schiorring E, Randrup A (1971). Social isolation and changes in the formation of groups induced by amphetamine in an open-field test with rats. Pharmakopsychiatr Neuropsychopharmakol 4:1-11.
86. Schlemmer-RF J, Davis JM (1983). A comparison of three psychotomimetic-induced models of psychosis in nonhuman primate social colonies. In: Ethopharmacology: Primate Models of Neuropsychiatric Disorders. Miczek KA (editor). New York: Alan R. Liss, pp. 33-78.
87. Schwarzkopf SB, Mitra T, Bruno JP (1992). Sensory gating in rats depleted of dopamine as neonates: potential relevance to findings in schizophrenic patients. Biol Psychiatry 31:759-773.
88. Scraggs P, Ridley RM (1979). The effect of dopamine and noradrenaline blockade on amphetamine induced behaviour in the marmoset. Psychopharmacology 62:41-45.
89. Sofia RD, Knobloch LC (1976). Comparative effects of various naturally occurring cannabinoids on food, sucrose and water consumption by rats. Pharmacol Biochem Behav 4:591-599.
90. Spatz M, Laquer GL (1968). Transplacental chemical induction of microencephaly in two strains of rats. Proc Soc Exp Biol Med 129:705-710.
91. Stahle L, Ungerstedt U (1990). Yawning and suppression of exploration induced by dopamine agonists: no relation to extracellular striatal levels of dopamine. Pharmacol Biochem Behav 35:201-209.
92. Steinpreis RE, Sokolowski JD, Papanikolaou A, Salamone JD (1994). The effects of haloperidol and clozapine on PCP-and amphetamine-induced suppression of social behavior in the rat. Pharmacol Biochem Behav 47:579-585.
93. Strauss JS, Kokes RF, Klorman R, Sacksteder JL (1977). Premorbid adjustment in schizophrenia: concepts, measures and implications. I. The concept of premorbid adjustment. Schizophr Bull 3:182-185.
94. Swerdlow NR, Bakshi V, Waikar M, Taaid N, Geyer MA (1998). Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacology 140:75-80.
95. Talamini L, Koch T, ter HG, Korf J (1998). Methylazoxymethanol acetate-induced abnormalities in the entorhinal cortex of the rat: parallels with morphological findings in schizophrenia. Brain Res 789:293-306.
96. Talamini L, Ellenbroek BA, Koch T, Korf J (2000). Impaired sensory gating and attention in rats with developmental abnormalities of the mesocortex: implications for schizophrenia. Ann NY Acad Sci, in press.
97. Tollefson GD, Sanger TM (1997). Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154:466-474.
98. Turgeon SM, Auerbach EA, Heller MA (1998). The delayed effects of phencyclidine (PCP) disrupt latent inhibition in a conditioned taste aversion paradigm. Pharmacol Biochem Behav 60:553-558.
99. Van den Berg CL, Pijlman FTA, Koning HAM, Diergaarde L, Van Ree JM, Spruijt BM (1999). Isolation changes the incentive value of sucrose and social behaviour in juvenile and adult rats. Behav Brain Res 106:133-142.
100. vanKammen DP, Boronow JJ (1988). Dextro-amphetamine diminishes negative symptoms in schizophrenia. Int Clin Psychopharmacol 3:111-121.
101. Varty GB, Higgins GA (1995). Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs. Psychopharmacology 122:15-26.
102. Walker EF, Diforio D (1997). Schizophrenia: a neural diathesis-stress model. Psychol Rev 104:667-685.
103. Wauquier A (1979). Neuroleptics and brain self-stimulation behavior. Int Rev Neurobiol 21:335-403.
104. Weinberger DR (1996). On the plausibility of 'the neurodevelopmental hypothesis' of schizophrenia. Neuropsychopharmacology 14:1S-11S.
105. Willner P (1984). The validity of animals models of depression. Psychopharmacology 83:1-16.
106. Willner P, Phillips G, Muscat R (1991). Suppression of rewarded behaviour by neuroleptic drugs: can't or won't, and why? In: The Mesolimbic Dopamine System: From Motivation to Action. Willner P, Scheel KJ (editors). Chichester: John Wiley and Sons, pp. 251-271.
107. Wise RA (1982). Neuroleptics and operant behavior: the anhedonia hypothesis. Behav Brain Sci 5:39-87.
108. Wongwitdecha N, Marsden CA (1996). Social isolation increases aggressive behaviour and alters the effects of diazepam in the rat social interaction test. Behav Brain Res 75:27-32.